


COLORECTAL CANCER

2598 samples - 9.65 % of the cohort (P: 1750 - 67.4 % | M: 836 - 32.2 %)


2172 samples with TP53 hits (P: 1415 - 65.1 % | M: 751 - 34.6 %)



GERM CELL TUMOR

331 samples - 1.23 % of the cohort (P: 199 - 60.1 % | M: 132 - 39.9 %)






279 samples with TP53 hits (P: 160 - 57.3 % | M: 119 - 42.7 %)



GASTROINTESTINAL STROMAL TUMOR

391 samples - 1.45 % of the cohort (P: 235 - 60.1 % | M: 155 - 39.6 %)

119 samples with TP53 hits (P: 55 - 46.2 % | M: 63 - 52.9 %)




MELANOMA

969 samples - 3.6 % of the cohort (P: 271 - 28.0 % | M: 693 - 71.5 %)


493 samples with TP53 hits (P: 120 - 24.3 % | M: 369 - 74.8 %)







SMALL CELL LUNG CANCER
267 samples - 0.99 % of the cohort (P: 126 - 47.2 % | M: 141 - 52.8 %)
260 samples with TP53 hits (P: 124 - 47.7 % | M: 136 - 52.3 %)




798 samples - 2.96 % of the cohort (P: 475 - 59.5 % | M: 323 - 40.5 %)
437 samples with TP53 hits (P: 260 - 59.5 % | M: 177 - 40.5 %)




218 samples - 0.81 % of the cohort (P: 180 - 82.6 % | M: 37 - 17.0 %)
101 samples with TP53 hits (P: 80 - 79.2 % | M: 20 - 19.8 %)



ENDOMETRIAL CANCER
886 samples - 3.29 % of the cohort (P: 591 - 66.7 % | M: 294 - 33.2 %)
474 samples with TP53 hits (P: 304 - 64.1 % | M: 170 - 35.9 %)



ESOPHAGOGASTRIC CANCER
605 samples - 2.25 % of the cohort (P: 440 - 72.7 % | M: 164 - 27.1 %)
527 samples with TP53 hits (P: 383 - 72.7 % | M: 143 - 27.1 %)




SKIN CANCER, NON-MELANOMA
198 samples - 0.74 % of the cohort (P: 96 - 48.5 % | M: 101 - 51.0 %)
120 samples with TP53 hits (P: 54 - 45.0 % | M: 66 - 55.0 %)



GLIOMA

1384 samples - 5.14 % of the cohort (P: 1283 - 92.7 % | M: 95 - 6.9 %)


568 samples with TP53 hits (P: 528 - 93.0 % | M: 38 - 6.7 %)




BLADDER CANCER

817 samples - 3.03 % of the cohort (P: 639 - 78.2 % | M: 177 - 21.7 %)




569 samples with TP53 hits (P: 437 - 76.8 % | M: 132 - 23.2 %)






NON-SMALL CELL LUNG CANCER
3403 samples - 12.64 % of the cohort (P: 2057 - 60.4 % | M: 1337 - 39.3 %)
2590 samples with TP53 hits (P: 1441 - 55.6 % | M: 1145 - 44.2 %)



3668 samples - 13.62 % of the cohort (P: 1890 - 51.5 % | M: 1776 - 48.4 %)
2724 samples with TP53 hits (P: 1331 - 48.9 % | M: 1391 - 51.1 %)



206 samples - 0.76 % of the cohort (P: 111 - 53.9 % | M: 93 - 45.1 %)
123 samples with TP53 hits (P: 70 - 56.9 % | M: 53 - 43.1 %)















OVARIAN CANCER
835 samples - 3.1 % of the cohort (P: 353 - 42.3 % | M: 477 - 57.1 %)
712 samples with TP53 hits (P: 286 - 40.2 % | M: 423 - 59.4 %)



PROSTATE CANCER

1335 samples - 4.96 % of the cohort (P: 713 - 53.4 % | M: 620 - 46.4 %)




761 samples with TP53 hits (P: 345 - 45.3 % | M: 415 - 54.5 %)



HEAD AND NECK CANCER
337 samples - 1.25 % of the cohort (P: 150 - 44.5 % | M: 185 - 54.9 %)
205 samples with TP53 hits (P: 98 - 47.8 % | M: 106 - 51.7 %)








PERIPHERAL NERVOUS SYSTEM
171 samples - 0.63 % of the cohort (P: 87 - 50.9 % | M: 84 - 49.1 %)
85 samples with TP53 hits (P: 44 - 51.8 % | M: 41 - 48.2 %)



THYROID CANCER

384 samples - 1.43 % of the cohort (P: 159 - 41.4 % | M: 225 - 58.6 %)

154 samples with TP53 hits (P: 76 - 49.4 % | M: 78 - 50.6 %)



HEPATOBIILIARY CANCER

670 samples - 2.49 % of the cohort (P: 474 - 70.7 % | M: 195 - 29.1 %)







397 samples with TP53 hits (P: 268 - 67.5 % | M: 128 - 32.2 %)



RENAL CELL CARCINOMA
598 samples - 2.22 % of the cohort (P: 393 - 65.7 % | M: 204 - 34.1 %)
265 samples with TP53 hits (P: 163 - 61.5 % | M: 101 - 38.1 %)








PANCREATIC CANCER
1202 samples - 4.46 % of the cohort (P: 610 - 50.7 % | M: 591 - 49.2 %)
967 samples with TP53 hits (P: 481 - 49.7 % | M: 486 - 50.3 %)



CANCER OF UNKNOWN PRIMARY
753 samples - 2.8 % of the cohort (P: 80 - 10.6 % | M: 673 - 89.4 %)
537 samples with TP53 hits (P: 54 - 10.1 % | M: 483 - 89.9 %)



92 samples with TP53 hits (P: 30 - 32.6 % | M: 62 - 67.4 %)



UTERINE SARCOMA
178 samples - 0.66 % of the cohort (P: 81 - 45.5 % | M: 96 - 53.9 %)
109 samples with TP53 hits (P: 56 - 51.4 % | M: 53 - 48.6 %)

